Millions of people in the United States and several other countries are currently taking GLP 1 drugs for weight management and diabetes care. These medications have become one of the fastest growing segments in both primary care and specialty clinics.
As demand rises, health systems, payers, and patients want clearer visibility into how many people are on GLP 1 drugs, how treatment looks in practice, and what this means for outcomes and costs. The following overview brings together national estimates, clinic level patterns, and service structures that shape today’s GLP 1 landscape.
| Region or Setting | Estimated People on GLP 1 Drugs | Key Drug Classes Included | Data Source and Date |
|---|---|---|---|
| United States | Over 30 million | Semaglutide, Tirzepatide, Liraglutide, Dulaglutide | IQVIA, 2024 |
| United Kingdom | Over 1 million | Semaglutide, Liraglutide | NHS Digital, 2023 |
| Canada | Over 800,000 | Semaglutide, Liraglutide, Dulaglutide | Canadian Institute for Health Information, 2023 |
| Commercial health plans (US) | Approximately 1 in 10 insured adults | Primarily Semaglutide and Tirzepatide | Employer and payer surveys, 2024 |
Clinical Use and Patient Populations
GLP 1 drugs were initially approved for type 2 diabetes and have since expanded into weight management and cardiovascular risk reduction. Understanding the patient mix helps explain the scale of use across different care settings.
People with Type 2 Diabetes
Among adults with type 2 diabetes, GLP 1 agonists are now first line options alongside metformin and SGLT2 inhibitors, especially when weight or cardiovascular risk are concerns. Large registries show steady increases in adoption over the past five years.
People Using GLP 1 Drugs for Weight
Newer indications and higher doses have driven strong demand from people without diabetes who are managing obesity or overweight conditions. This group now represents a large share of new prescriptions in many markets.
Prescribing Patterns and Geography
Prescribing of GLP 1 drugs varies by region, influenced by local guidelines, primary care capacity, and the presence of specialized weight management or diabetes programs. Urban centers often report higher initial uptake, while rural areas are catching up as telehealth and mail order services expand.
Health systems track usage through formularies and EHR data, which help forecast budget needs and staffing. National surveys indicate that uptake in primary care offices has accelerated, making GLP 1 drugs a routine option rather than a specialist only therapy.
Access, Cost, and Payer Coverage
Access to GLP 1 drugs depends heavily on insurance coverage, prior authorization policies, and pharmacy benefit manager arrangements. Many plans now include these medications on preferred tiers, but step therapy and quantity limits can still create delays for people starting treatment.
| Payer Type | Typical Coverage Status | Prior Authorization Likelihood | Patient Cost Sharing Pattern |
|---|---|---|---|
| Commercial Insurance | Covered with restrictions | Moderate to high | Copays influenced by plan tier |
| Medicare | Covered for diabetes and weight | Required in many plans | 20 percent coinsurance after deductible |
| Medicaid | Varies by state | Low to moderate in expanded programs | Copays may be limited or waived |
| Uninsured | Full self pay | N/A | High out of pocket costs |
Safety, Side Effects, and Monitoring
GLP 1 drugs are generally well tolerated, but people experience side effects such as nausea, vomiting, and constipation, especially when starting therapy. Clinics often use slow dose titration and structured follow up to manage these effects and support adherence.
Monitoring includes periodic review of blood sugar, kidney function, and cardiovascular symptoms, particularly for people with complex health conditions. Care teams also track mental health and quality of life indicators, recognizing that weight and diabetes management are closely tied to overall wellbeing.
Future Outlook and Recommendations
The continued expansion of GLP 1 drugs will shape diabetes, obesity, and cardiovascular care for years. Stakeholders across health systems, payers, and policy need coordinated strategies to support safe, equitable access.
- Monitor national and regional usage trends to anticipate capacity needs
- Streamline prior authorization processes in partnership with payers
- Invest in primary care training and telehealth infrastructure
- Implement standardized follow up protocols for dose titration and side effect management
- Track patient reported outcomes related to quality of life and mental health
FAQ
Reader questions
How many people in the United States are currently using GLP 1 drugs?
Over 30 million people in the United States are using GLP 1 drugs as of 2024, based on national pharmacy and healthcare utilization data.
Are GLP 1 drugs covered for weight loss by most insurance plans?
Many commercial plans cover GLP 1 drugs for weight loss, but coverage often requires prior authorization and may include quantity limits or step therapy protocols.
What are the most common side effects people experience on GLP 1 treatment?
Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects, especially during the initial weeks of dose escalation.
How does access to GLP 1 drugs differ between urban and rural areas?
Access is generally faster in urban areas due to more specialty clinics and telehealth options, while rural patients often rely on primary care and mail order pharmacy services.